PE142000: α-GalNAc-PEG4-Acid label-new HCl / N-[2-Butyl-3-[4-[3-(butylamino)propoxybenzoyl]-5-benzofuranyl]-methanesulfonamide-d6 Hydrochloride

HCl / N-[2-Butyl-3-[4-[3-(butylamino)propoxybenzoyl]-5-benzofuranyl]-methanesulfonamide-d6 Hydrochloride

2-[2-(2-Azidoethoxy)ethoxy]ethyl 2-acetamido-2-deoxy-β-D-galactopyranoside

2-[2-(2-Azidoethoxy)ethoxy]ethyl β-D-glucopyranoside

36 / A β-D-N-acetylgalactosamine (GalNAcβ) ligand equipped with an amine-functionalized linker through a pentyl spacer

32 / A β-D-galactose ligand equipped with a terminal carboxylic acid through a hydrophilic PEG3 spacer

PE142000: α-GalNAc-PEG4-Acid label-new HCl / N-[2-Butyl-3-[4-[3-(butylamino)propoxybenzoyl]-5-benzofuranyl]-methanesulfonamide-d6 HydrochlorideC17H31NO11 425. 43 An D N acetylgalactosamine (GalNAc) ligand equipped with a terminal carboxylic acid through a hydrophilic PEG4 spacer. The carboxylic acid can be activated to NHS, sulfo NHS, or pentafluorophenyl esters and reacted with amine functionalized platforms or lysine residues on proteins and peptides to form amide bonds. This compound enables the construction of hepatocyte targeted therapeutics and research tools that exploit the